Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 16,836 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: HIV Infections
Interventions: HIVAX, saline solution; Biological
Lead sponsor: GeneCure Biotechnologies; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, T-Cell, Juvenile Myelomonocytic Leukemia Lymphoblastic, T-cell Lymphoblastic Lymphoma, Myelodysplastic Syndrome
Interventions: Haploidentical donor derived natural killer cell infusion, Chemotherapy, CliniMACS; Procedure · Drug · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Staphylococcus Aureus, Staphylococcal Skin Infections, Bacteremia
Interventions: Not listed
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fanconi's Anemia
Interventions: amifostine; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 2 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Adefovir dipivoxil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 27
States / cities: Birmingham, Alabama • Berkeley, California • Los Angeles, California + 22 more

Conditions: Obstructive Sleep Apnea
Interventions: continuous positive airway pressure (CPAP); Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hiv, Violence
Interventions: WMR; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Sepsis
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Toxoplasmosis, Cerebral, HIV Infections
Interventions: Pyrimethamine, Leucovorin calcium, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 2
States / cities: New York, New York • Chapel Hill, North Carolina

Conditions: Sleep Apnea, Obstructive
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma
Interventions: Pralatrexate Injection, Bexarotene Capsules, Vitamin B12, Folic Acid; Drug · Dietary Supplement
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 4
States / cities: Stanford, California • New York, New York • Pittsburgh, Pennsylvania + 1 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Los Angeles, California • Menlo Park, California • San Diego, California + 15 more

Conditions: Leukemia
Interventions: filgrastim, cladribine, cytarabine, etoposide, methotrexate, mitoxantrone hydrochloride, therapeutic hydrocortisone, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2008
U.S. locations: 35
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 27 more

Conditions: Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS)
Interventions: S64315 once a week, S64315 twice a week; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut • Houston, Texas

Conditions: Chronic Graft Versus Host Disease, cGVHD
Interventions: Axatilimab, Extracorporeal Photopheresis; Biological · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 12 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: San Francisco, California • Miami, Florida • Chicago, Illinois

Conditions: Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease
Interventions: Maralixibat; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 0 Days to 364 Days
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more

Conditions: Chronic Neuropathic Pain, Post-Stroke Pain, Trigeminal Neuralgia, Nerve Injury, Spinal Cord Injuries, Pain, Postoperative, Complex Regional Pain Syndromes, Post-herpetic Neuralgia, Nerve Root Avulsion
Interventions: High Frequency rTMS, Low Frequency rTMS; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: EP-1233, MVA-mBN32; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: San Francisco, California • Rochester, New York • Nashville, Tennessee

Conditions: Immunodeficiency, Hematopoietic Stem Cell Transplantation
Interventions: Allogeneic HSCT, Busulfan test dose, Mycophenolate mofetil (MMF), Tacrolimus, Busulfan, Total Body Irradiation (TBI), Fludarabine, Cyclophosphamide (CY), Post-Transplant Cyclophosphamide (PTCY); Procedure · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Child Development Disorders, Pervasive
Interventions: Risperidone, Behavior Therapy; Drug · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 4 Years to 13 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 3
States / cities: New Haven, Connecticut • Indianapolis, Indiana • Columbus, Ohio

Conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Interventions: Akt/ERK Inhibitor ONC201, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sickle Cell Disease, Asthma, Acute Chest Syndrome
Interventions: Budesonide inhalation suspension; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 1 Year to 4 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Epilepsy, Dravet Syndrome
Interventions: GWP42003-P 20 mg/kg/day Dose, Placebo control; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 13
States / cities: Miami, Florida • Orlando, Florida • Atlanta, Georgia + 10 more

Conditions: Myasthenia Gravis, Generalized
Interventions: Aritinercept, Placebo; Drug · Other
Lead sponsor: Aurinia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: Pasadena, California • Altamonte Springs, Florida • Boca Raton, Florida + 7 more

Search by objective public record fields.

Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects

Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors

Rapid Test to Detect Staphylococcus Aureus in Blood and Wound Infections

Phase I Study of Amifostine in Patients With Bone Marrow Failure Related to Fanconi's Anemia

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3

Autonomic Function in Obstructive Sleep Apnea

Within My Reach (WMR) Adaptation

Evaluation of the Patient Safety Screening Tool (PSST) for Sepsis

A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients

Predicting Outcomes in Hypoglossal Nerve Stimulation Therapy With Stimulated Upper Airway Mechanics

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV Therapy

Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

Transcranial Magnetic Stimulation for Chronic Neuropathic Pain

Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

Study of Aritinercept in Patients With Generalized Myasthenia Gravis